Literature DB >> 29191832

Molecular characterization of human anti-hinge antibodies derived from single-cell cloning of normal human B cells.

Tao Huang1, Mary Mathieu1, Sophia Lee1, Xinhua Wang1, Yee Seir Kee1, Jack J Bevers1, Claudio Ciferri2, Alberto Estavez2, Manda Wong2, Nancy Y Chiang1, Gerald Nakamura1, Randall J Brezski3.   

Abstract

Anti-hinge antibodies (AHAs) are an autoantibody subclass that, following proteolytic cleavage, recognize cryptic epitopes exposed in the hinge regions of immunoglobulins (Igs) and do not bind to the intact Ig counterpart. AHAs have been postulated to exacerbate chronic inflammatory disorders such as inflammatory bowel disease and rheumatoid arthritis. On the other hand, AHAs may protect against invasive microbial pathogens and cancer. However, despite more than 50 years of study, the origin and specific B cell compartments that express AHAs remain elusive. Recent research on serum AHAs suggests that they arise during an active immune response, in contrast to previous proposals that they derive from the preexisting immune repertoire in the absence of antigenic stimuli. We report here the isolation and characterization of AHAs from memory B cells, although anti-hinge-reactive B cells were also detected in the naive B cell compartment. IgG AHAs cloned from a single human donor exhibited restricted specificity for protease-cleaved F(ab')2 fragments and did not bind the intact IgG counterpart. The cloned IgG-specific AHA-variable regions were mutated from germ line-derived sequences and displayed a high sequence variability, confirming that these AHAs underwent class-switch recombination and somatic hypermutation. Consistent with previous studies of serum AHAs, several of these clones recognized a linear, peptide-like epitope, but one clone was unique in recognizing a conformational epitope. All cloned AHAs could restore immune effector functions to proteolytically generated F(ab')2 fragments. Our results confirm that a diverse set of epitope-specific AHAs can be isolated from a single human donor.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  antibody engineering; autoimmunity; immunogenicity; immunoglobulin G (IgG); monoclonal antibody

Mesh:

Substances:

Year:  2017        PMID: 29191832      PMCID: PMC5777262          DOI: 10.1074/jbc.RA117.000165

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Specificity of human anti-variable heavy (VH ) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-α receptor 1.

Authors:  J C Cordy; P J Morley; T J Wright; M A Birchler; A P Lewis; R Emmins; Y Z Chen; W M Powley; P J Bareille; R Wilson; J Tonkyn; A I Bayliffe; A L Lazaar
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

2.  In vivo antigen-driven plasmablast enrichment in combination with antigen-specific cell sorting to facilitate the isolation of rare monoclonal antibodies from human B cells.

Authors:  Zhonghua Lin; Nancy Y Chiang; Ning Chai; Dhaya Seshasayee; Wyne P Lee; Mercedesz Balazs; Gerald Nakamura; Lee R Swem
Journal:  Nat Protoc       Date:  2014-06-05       Impact factor: 13.491

3.  The covalent structure of an entire gammaG immunoglobulin molecule.

Authors:  G M Edelman; B A Cunningham; W E Gall; P D Gottlieb; U Rutishauser; M J Waxdal
Journal:  Proc Natl Acad Sci U S A       Date:  1969-05       Impact factor: 11.205

4.  Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1.

Authors:  M C Holland; J U Wurthner; P J Morley; M A Birchler; J Lambert; M Albayaty; A P Serone; R Wilson; Y Chen; R M Forrest; J C Cordy; D A Lipson; A I Bayliffe
Journal:  J Clin Immunol       Date:  2013-07-06       Impact factor: 8.317

5.  The antigen-binding domain of a human IgG-anti-F(ab')2 autoantibody.

Authors:  M Welschof; P Terness; S M Kipriyanov; D Stanescu; F Breitling; H Dörsam; S Dübel; M Little; G Opelz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

6.  The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge.

Authors:  Randall J Brezski; Allison Oberholtzer; Brandy Strake; Robert E Jordan
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

7.  Ex vivo characterization and isolation of rare memory B cells with antigen tetramers.

Authors:  Bettina Franz; Kenneth F May; Glenn Dranoff; Kai Wucherpfennig
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

Review 8.  Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?

Authors:  Randall J Brezski; Robert E Jordan
Journal:  MAbs       Date:  2010-05-23       Impact factor: 5.857

Review 9.  Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors:  Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal:  MAbs       Date:  2015       Impact factor: 5.857

10.  RELION: implementation of a Bayesian approach to cryo-EM structure determination.

Authors:  Sjors H W Scheres
Journal:  J Struct Biol       Date:  2012-09-19       Impact factor: 2.867

View more
  3 in total

1.  Design, construction and in vivo functional assessment of a hinge truncated sFLT01.

Authors:  Fahimeh Zakeri; Hamid Latifi-Navid; Zahra-Soheila Soheili; Mehdi Sadeghi; Seyed Shahriar Arab; Shahram Samiei; Ehsan Ranaei Pirmardan; Sepideh Taghizadeh; Hamid Ahmadieh; Ali Hafezi-Moghadam
Journal:  Gene Ther       Date:  2022-09-16       Impact factor: 4.184

2.  Autoantibodies against the Immunoglobulin-Binding Region of Ro52 Link its Autoantigenicity with Pathogen Neutralization.

Authors:  Peter D Burbelo; Leyla Y Teos; Jesse L Herche; Michael J Iadarola; Ilias Alevizos
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.996

Review 3.  Proteinase-nicked IgGs: an unanticipated target for tumor immunotherapy.

Authors:  Robert E Jordan; Xuejun Fan; Georgina Salazar; Ningyan Zhang; Zhiqiang An
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.